News
Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...
16h
TipRanks on MSNKeros Therapeutics’ treatment of Duchenne MD granted FDA orphan designation
Keros Therapeutics (KROS)’ treatment of Duchenne muscular dystrophy was granted FDA orphan designation, according to a post to the agency’s site.
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is pleased to announce the expansion of its leadership team with the ...
18d
MedPage Today on MSNBone Health in Duchenne Muscular Dystrophy
Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to disease-related loss of muscle and movement, adverse effects of ...
Dyne Therapeutics Inc. (NASDAQ: DYN) is one of the best small cap stocks with biggest upside potential. On August 4, Dyne ...
4h
News-Medical.Net on MSNImproving gene therapy safety with human kidney organoids
Ryuji Morizane, MD, PhD, of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author ...
The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency ...
Charlie has Duchenne muscular dystrophy, a degenerative genetic disease that, until recently, has guaranteed death by early adulthood from cardiac or respiratory failure.
Dr. Jerry Mendell, who co-invented the gene therapy, said "treating boys with Duchenne muscular dystrophy after seeing their natural history and decline over and over and over for the past 50 ...
Teen whose story touched Post readers gets up-close look at planes and hangars, joining his friends for ‘special’ visit he helped to organise.
After decades of research, gene therapy has been approved for Duchenne Muscular Dystrophy, a degenerative muscle disease diagnosed each year in about 1 in 3,500 newborns, almost all boys.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results